Saudi Arabia welcomes trilateral border treaty between Tajikistan, Kyrgyzstan, and Uzbekistan    Trump prepares to unveil sweeping new US tariffs on 'Liberation Day'    At least 22 civilians killed in Israeli strike on UNRWA clinic in Gaza    UK says it won't jump into US trade war as Starmer urges calm response to tariffs    Russia, Ukraine trade fresh accusations of violating US-brokered energy ceasefire deal    Swedish table tennis legend Jörgen Persson appointed head coach of Saudi national team    Danilo Pereira fires Al Ittihad into King's Cup final with dramatic stoppage-time double    Over 1 million pilgrims benefit from golf cart service at Grand Mosque during Ramadan    Visitors welcomed with Eid initiative at Thee Ain Heritage Village in Al-Baha    Tebuk emir reviews rain response in Tayma    Saudi Arabia considers rent cap as part of major real estate reforms    Messi's bodyguard banned from touchline at Inter Miami games    Screen time in bed linked to insomnia, study finds    Haramain High-Speed Railway transports over 1.2 million passengers during Ramadan    Saudi Transport Authority says passengers can ride for free if taxi meters are off    Ministry of Education forms 425 community partnerships with SR653 million impact    Mexico bans junk food in schools to fight childhood obesity epidemic    Sweet sales surge ahead of Eid as Saudi chocolate imports top 123 million kg in 2024    Saudi creatives shine at Jeddah's Fawanees Nights with art, fashion, and storytelling    T1 CEO confirms Gumayusi's return for LCK Spring after lineup shakeup    Bollywood actress vindicated over boyfriend's death after media hounding    Grand Mufti rules against posting prayers and preaching in mosques on social media    King Salman prays for peace and stability for Palestinians in Ramadan message King reaffirms Saudi Arabia's commitment to serving the Two Holy Mosques and pilgrims    Bollywood star Saif Ali Khan 'out of danger' after attack at home in Mumbai    Exotic Taif Roses Simulation Performed at Taif Rose Festival    Asian shares mixed Tuesday    Weather Forecast for Tuesday    Saudi Tourism Authority Participates in Arabian Travel Market Exhibition in Dubai    Minister of Industry Announces 50 Investment Opportunities Worth over SAR 96 Billion in Machinery, Equipment Sector    HRH Crown Prince Offers Condolences to Crown Prince of Kuwait on Death of Sheikh Fawaz Salman Abdullah Al-Ali Al-Malek Al-Sabah    HRH Crown Prince Congratulates Santiago Peña on Winning Presidential Election in Paraguay    SDAIA Launches 1st Phase of 'Elevate Program' to Train 1,000 Women on Data, AI    41 Saudi Citizens and 171 Others from Brotherly and Friendly Countries Arrive in Saudi Arabia from Sudan    Saudi Arabia Hosts 1st Meeting of Arab Authorities Controlling Medicines    General Directorate of Narcotics Control Foils Attempt to Smuggle over 5 Million Amphetamine Pills    NAVI Javelins Crowned as Champions of Women's Counter-Strike: Global Offensive (CS:GO) Competitions    Saudi Karate Team Wins Four Medals in World Youth League Championship    Third Edition of FIFA Forward Program Kicks off in Riyadh    Evacuated from Sudan, 187 Nationals from Several Countries Arrive in Jeddah    SPA Documents Thajjud Prayer at Prophet's Mosque in Madinah    SFDA Recommends to Test Blood Sugar at Home Two or Three Hours after Meals    SFDA Offers Various Recommendations for Safe Food Frying    SFDA Provides Five Tips for Using Home Blood Pressure Monitor    SFDA: Instant Soup Contains Large Amounts of Salt    Mawani: New shipping service to connect Jubail Commercial Port to 11 global ports    Custodian of the Two Holy Mosques Delivers Speech to Pilgrims, Citizens, Residents and Muslims around the World    Sheikh Al-Issa in Arafah's Sermon: Allaah Blessed You by Making It Easy for You to Carry out This Obligation. Thus, Ensure Following the Guidance of Your Prophet    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



First pill to treat Covid gets approval in UK
Published in The Saudi Gazette on 04 - 11 - 2021

The first pill designed to treat symptomatic Covid has been approved by the UK medicines regulator, BBC reported.
The tablet -- molnupiravir -- will be given twice a day to vulnerable patients recently diagnosed with the disease.
In clinical trials the pill, originally developed to treat flu, cut the risk of hospitalization or death by about half.
Health Secretary Sajid Javid said the treatment was a "gamechanger" for the most frail and immunosuppressed.
In a statement he said: "Today is a historic day for our country, as the UK is now the first country in the world to approve an antiviral that can be taken at home for Covid."
Molnupiravir, developed by the US drug companies Merck, Sharp and Dohme (MSD) and Ridgeback Biotherapeutics, is the first antiviral medication for Covid which can be taken as a pill rather than injected or given intravenously.
The UK has agreed to purchase 480,000 courses with the first deliveries expected in November.
Initially it will be given to both vaccinated and unvaccinated patients through a national study, with extra data on its effectiveness collected before any decision to order more.
The drug needs to be given within five days of symptoms developing to be most effective.
It's not immediately clear how it will be distributed so quickly by the NHS. It's thought some care homes may be offered supplies while other elderly or vulnerable patients may be prescribed it by their GP after testing positive for Covid.
Molnupiravir, developed by scientists at Ridgeback Biotherapeutics and MSD, is the first of a number of oral antiviral treatments for Covid to report clinical trial results.
The new treatment targets an enzyme that the virus uses to make copies of itself, introducing errors into its genetic code. That should prevent it from multiplying, so keeping virus levels low in the body and reducing the severity of the disease.
Merck said that approach should make the treatment equally effective against new variants of the virus as it evolves in the future.
The UK regulator, the MHRA, said the tablet had been authorized for use in people who have mild to moderate Covid and at least one risk factor for developing severe illness such as obesity, old age, diabetes or heart disease.
The organization's chief executive, June Raine, described it as "another therapeutic to add to our armory against Covid-19".
"It is the world's first approved antiviral for this disease that can be taken by mouth rather than administered intravenously," she said.
"This is important because it means it can be administered outside of a hospital setting, before Covid-19 has progressed to a severe stage."
England's deputy chief medical officer, Prof Jonathan Van-Tam, warned on Wednesday of some "hard months to come" in the pandemic.
He said that while Covid cases appeared to have stabilized, deaths were rising and there were signs infections were starting to "penetrate" older age groups.
The UK recorded 41,229 Covid cases on Wednesday and 217 deaths within 28 days of a positive test.
The results were published in a press release and have not yet been peer-reviewed.
But data suggest molnupiravir needs to be taken soon after symptoms develop to have an effect. An earlier study in patients who had already been hospitalized with severe Covid was halted after disappointing results.
In its approval document, the MHRA recommends the drug is used "as soon as possible" following a positive Covid test and within five days of symptoms onset.
Prof Penny Ward, from King's College London, who was not involved in the study, said: "If these outcomes are replicated in the UK population, then the number of cases requiring hospital admission could be halved and the number of deaths greatly reduced.
"It seems likely that it will be restricted for use by those at highest risk of disease complications -- for example older adults with heart, lung or kidney disease, diabetes or cancer."
The UK government has not disclosed how much its initial contract for 480,000 courses of molnupiravir is worth. But US authorities recently made an advance purchase of 1.7 million courses at a cost of roughly $1.2 billion, or $700 (£513) for each patient.
Other countries including Australia, Singapore and South Korea have also made purchase agreements.
Merck is the first company to report trial results of a pill to treat Covid, but other companies are working on similar treatments.
Its US rival Pfizer has started trials of two different antiviral tablets, while Swiss company Roche is working on a similar medication.


Clic here to read the story from its source.